Stay updated with breaking news from Marc Semigran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel...
![Think about genetics in heart disease [PODCAST] - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Marc Semigran is a cardiologist and chief medical officer of a biotechnology company developing cardiac gene therapy.He shares his story and discusses his KevinMD article, "It’s time to start approaching heart disease like breast cancer."
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
Published: Jun 03, 2021 By Alex Keown 180 Life Sciences -- Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Of...
Genomic Advances in Heart Failure, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss recent advances in heart failure genomics including improved diagnostic techniques and therapies. They will present findings from whole-genome sequencing data and clinical data that are used to help scientists discover and validate new drug targets for heart failure. The speakers will discuss what is currently known about genomic drivers of heart failure and opportunities for novel therapeutics being explored in their own research programs. ...